Celyad Oncology S.A.
CLYYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.01 | -0.04 | -0.05 |
| FCF Yield | -19.26% | -160.50% | -246.08% | -49.29% |
| EV / EBITDA | -7.95 | -0.53 | 0.02 | -1.08 |
| Quality | ||||
| ROIC | -83.03% | -76.73% | -308.66% | -38.87% |
| Gross Margin | 494.09% | 32.35% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 1.80 | 0.68 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 64.72% | 42.77% | -4.06% | 3.39% |
| Safety | ||||
| Net Debt / EBITDA | -2.47 | 0.77 | 0.31 | 1.08 |
| Interest Coverage | -52.60 | -126.15 | -149.61 | -103.49 |
| Efficiency | ||||
| Inventory Turnover | -1.76 | 0.05 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,188.16 | 1,449.73 | -1,204.50 | -1,587.51 |